ClearShares Ultra-Short Maturity ETF OPER 深 沪
已收盘 11-06 16:00:00 美东时间
100.135
+0.020
+0.02%
华盛通- 最 高100.14
- 今 开100.14
- 成交量 2193股
- 最 低 100.12
- 昨 收 100.115
- 总市值 1.13亿
- 52周最高 100.14
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 96.4592
- 委 比 0.00%
- 总股本 112.50万
- 历史最高 100.14
- 量 比 0.41
- 振 幅 0.02%
- 历史最低 76.6979
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Friedman Industries, Incorporated Announces Second Quarter Results
Friedman Industries reported record financial results for the quarter and six months ended September 30, 2026, with net earnings of $15.6 million and $28.4 million, respectively. Sales reached $286.8 million and $526.8 million, up 88% and 83% year-over-year. Sales volume also set records, up 23% and 25% year-over-year. CEO Michael J. Taylor highlighted strong execution, customer demand, and contributions from Century Metals as key drivers. The co...
11-05 21:33
COMPX REPORTS THIRD QUARTER 2026 RESULTS
CompX International Inc. reported third-quarter 2026 net sales of $44.0 million, up from $40.0 million in 2025, with operating income rising to $6.4 million from $4.8 million. Net income was $5.4 million, or $.44 per share, compared to $4.2 million, or $.34 per share, in 2025. For the first nine months of 2026, net sales reached $128.2 million, up from $120.6 million, with operating income at $22.4 million versus $17.0 million in 2025. Growth was...
11-04 21:15
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
FDA has granted priority review for uniQure's BLA for AMT-130 (ifezuntirgene inilparvovec) in Huntington's disease, with a PDUFA target action date of May 1, 2027. The company has aligned with FDA on the confirmatory study design and expects to begin patient screening in the U.S. by end of 2026. uniQure reported $768.4 million in cash, cash equivalents, and investment securities as of September 30, 2026, expected to fund operations into 2030. Thi...
11-04 12:05
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics submitted a Biologics License Application (BLA) for sonelokimab to treat moderate-to-severe hidradenitis suppurativa (HS) in adults and adolescents, marking a key step toward U.S. approval. Positive results from the Phase 3 IZAR-1 trial in psoriatic arthritis (PsA) were reported, with all clinical endpoints met for sonelokimab 60 mg with induction. Enrollment was completed in the Phase 3 IZAR-2 trial in PsA, with initi...
11-04 12:00
Cipher Mining(CIFR.US)Q3电话会：Barber Lake扩租至91亿美元合约，CEO称要为AI修高速、收数十年稳定过路费
周一美股盘前，Cipher Mining公布2026年第三季度业绩，并举行了财报电话会。
11-03 16:14
Magna to Host Investor Day on November 11, 2026
Magna International Inc. will host its 2026 Investor Day on November 11, 2026, in New York City. Key executives, including President and CEO Swamy Kotagiri and CFO Philip Fracassa, will present. The event will include a live webcast accessible via registration on www.magna.com/investorday2026-virtual. A replay and materials will be available post-event. Magna is a leading global automotive supplier with operations in 27 countries.
11-02 13:00
Koss Corporation Reports First Quarter Results
Koss Corporation reported a 24% decline in net sales for the first quarter ended September 30, 2026, to $3.09 million, resulting in a net loss of $234,168 compared to a net income of $243,729 in the prior year. The company noted strong domestic distributor sales but a lack of a significant education customer order. European sales remained stable, and direct-to-consumer (DTC) sales now account for 37% of total turnover. Gross margin decreased by 5...
10-29 21:15
Shell plc publishes third quarter 2026 press release
Shell reported strong third-quarter 2026 results, with adjusted earnings of $10.8 billion, driven by operational performance amid volatile commodity prices. The company completed the ARC Resources acquisition and announced a $5 billion share buyback program. Key highlights include record refining margins, $21 billion in cash flow, disciplined capital spending, and a strong balance sheet with net debt of $39.7 billion. Shell also secured a final i...
10-29 07:01
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Korro Bio announced preclinical results for KRRO-111, a potential treatment for alpha-1 antitrypsin deficiency (AATD). The study showed KRRO-111 restored functional M-AAT, reduced toxic Z-AAT by up to 95%, and achieved sustained RNA editing. It demonstrated the potential to address both lung and liver manifestations of AATD. Regulatory submission is expected in the first half of 2027.
10-22 11:00
IBM RELEASES THIRD-QUARTER RESULTS
Exceeded expectations with accelerated revenue growth led by Software and Infrastructure; Raises outlook for full-year free cash flow ARMONK, N.Y., Oct. 21, 2026 /PRNewswire/ -- IBM (NYSE: I...
10-22 04:08
